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strogen is a pleiotropic hormone that acts
beyond the scope of its reproductive functions and
exerts protective actions on multiple tissues including
the brain. The protective actions of estrogen carry
tremendous implications for the promotion of health
and the prevention of disease in postmenopausal
women. Since the life span of women has increased from
approximately 50 to 80 years, but the age of the
menopause remains at about 51 years, women may now
live over three decades of their lives in a hypoestrogenic,
postmenopausal state. The impact of prolonged hypo-
estrogenicity is now a critical health concern, since we
realize that these women may suffer from an increased
vulnerability to a variety of diseases. Conversely, replace-
ment with estrogen appears to act in the primary pre-
vention of many disease processes, including neuro-
degeneration. Estrogen, however, is not always beneficial,
as high and unopposed levels may increase the risk for
certain cancers in some women. Our challenge, therefore,
is to design hormone replacement therapies that exert
only beneficial effects in the body. To this end, we must
gain a more complete understanding of the spectrum of
estrogen’s actions and, more specifically, we must dissect
the mechanisms that underlie its actions.
The broad spectrum of estrogen’s actions includes sig-
nificant protection of the brain and primary prevention
against neurodegeneration. Clinical observations indi-
cate that estrogen replacement in postmenopausal
women can (i) ameliorate cognitive dysfunction, and (ii)
decrease the risk and delay the onset of degenerative
conditions such as Alzheimer’s disease (AD) and stroke.
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We now appreciate that estrogen is a pleiotropic gonadal
steroid that exerts profound effects on the plasticity and
cell survival of the adult brain. Over the past century, the
life span of women has increased, but the age of the
menopause remains constant. This means that women
may now live over one third of their lives in a hypoestro-
genic, postmenopausal state. The impact of prolonged
hypoestrogenicity on the brain is now a critical health
concern as we realize that these women may suffer an
increased risk of cognitive dysfunction and neurodegen-
eration due to a variety of diseases. Accumulating evi-
dence from both clinical and basic science studies indicates
that estrogen exerts critical protective actions against neuro-
degenerative conditions such as Alzheimer’s disease and
stroke. Here, we review the discoveries that comprise our
current understanding of estrogen action against neuro-
degeneration. These findings carry far-reaching possibili-
ties for improving the quality of life in our aging popula-
tion.
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Basic science studies have revealed a strong cellular and
molecular basis for these clinical observations. Recent
insights into the molecular events that underlie estro-
gen-mediated neuroprotection encompass actions that
range from its pharmacological, antioxidant mechanisms
to its physiological, estrogen receptor (ER)–dependent
mechanisms.The results of the studies that reveal estro-
gen’s neuroprotective actions and mechanisms carry
exciting and far-reaching possibilities for improving the
quality of life of our aging population. As we continue
to discover how estrogens act in the brain to promote
enhanced neural function and exert protective effects
against degeneration, we will be able to design hor-
mones that exert only beneficial effects in the body.
Estrogen, the menopause, and hormone
replacement
Estrogen
Estrogens are synthesized predominantly in the ovary as
18-carbon steroids with an aromatic A-ring.They act on
multiple endocrine targets and are synthesized in many
forms. Most clinical and basic science studies have
focused attention on the actions of estradiol, the most
potent and biologically active form of estrogen that cir-
culates in the body prior to the menopause.
Menopause
Because the menopause impacts the health of so many
women, investigators have focused on understanding the
driving factors that govern this change. For many years,
it was accepted that the menopause resulted simply from
the depletion of the postmitotic pool of ovarian follicles
that is set down during embryonic development.1 Clearly
the exhaustion of this reservoir necessarily means that a
woman is permanently postmenopausal and can no
longer produce offspring with her genetic makeup. As
importantly, since the ovarian follicles are not only the
source of germ cells, but are also the primary source of
estradiol, plasma concentrations of this hormone drop
precipitously during the postmenopausal years and
remain low for the remainder of a woman’s life, unless
she chooses to take hormone replacement therapy.
Whether or not the brain plays a role in the transition to
the menopause has been a topic of active debate. Results
from studies using animal models have suggested that
aging of the brain and a declining ability to provide
coordinated neurochemical signals that are required for
ovulation contribute to reproductive senescence. However,
whether these findings are relevant to the human
menopause has been less clear. Recently, an increasing
number of researchers have begun to appreciate that the
brain may play an important role in the sequence of
events leading to menopause in humans. Several find-
ings lead to this conclusion. First, the pattern of luteiniz-
ing hormone (LH) secretion and the levels of follicle-
stimulating hormone (FSH) secretion change before
women enter the perimenopausal period.These changes
are likely to reflect changes in the pattern of hypothala-
mic hormone secretion. Second, the responsiveness of
the brain to estradiol treatment and the ability of this
hormone to induce gonadotropin surges are greatly
compromised in middle-aged women as they enter the
transition to the menopause. Finally, estradiol concen-
trations remain normal or are elevated during the peri-
menopausal period, suggesting that the ovary remains
capable of secreting this critical hormone. Interestingly,
these findings are strikingly similar to what has been
observed in middle-aged laboratory rodents, as they
become less fertile and cease to have reproductive cycles.2
Since many studies to examine the role of the brain can-
not be performed in women because they are invasive
and involve experimental manipulations that cannot be
performed in humans, laboratory animals provide the
only means through which we can gain a better under-
standing of the role of the brain in the menopause. The
striking similarities between many of the events that
occur during middle age give us reason to believe that
rodents serve as excellent models in which to examine
the factors that initiate the process of reproductive aging
during middle age. We hope that information gained
from these species can be extrapolated to humans and
will allow us to uncover and explore concepts that can
be generalized to human reproductive aging.
Estrogen replacement therapy in postmenopausal
women
The process of reproductive aging in women ultimately
results in a hypoestrogenic, postmenopausal state. As
our understanding of estrogen action in the body grows,
the consequences of prolonged hypoestrogenicity and
the profound impact of estrogen replacement therapy
(ERT) on postmenopausal women become increasingly
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clear.We now know that, although estrogen can promote
disease in some women,3 it acts in a broad spectrum of
tissues to promote health and overall well-being.4-8 Insight
into many of the protective actions of estrogen is gained
from observations that oophorectomized young women
suffer increased pathophysiology, such as bone resorp-
tion,9 compared with their counterparts with normal
reproductive function. Further, hypoestrogenic, post-
menopausal women often suffer increased disease com-
pared with premenopausal women and age-matched
men. Studies demonstrate that estrogen acts in the brain
to enhance cognitive function and decrease the risk
and/or delay the onset of neurodegenerative condi-
tions.6,10-13 Further, estrogen decreases the risk and/or
mortality for cardiovascular disease, potentially through
its beneficial effects on the lipid profile and on the
endothelium,7,14,15 though recent evidence suggests that
estrogen-mediated protection of the heart may not per-
sist in women with preexisting cardiovascular disease.16
Finally, estrogen is crucial in the positive remodeling of
bone; the loss of estrogen in postmenopausal women is
accompanied by a dramatic increase in osteoporosis.5
Estrogen: effects on cognition and
Alzheimer’s disease
The focus of this review—and the focus of our recent
discoveries—is the action of estrogen in the injured and
aging brain. Our interest in this area stemmed from clin-
ical observations that estrogen acts beyond its traditional
targets in the hypothalamus and pituitary, and influences
other facets of brain function involved in memory and
neurodegeneration. Since neurodegenerative events
occur frequently in elderly women who are chronically
hypoestrogenic, the results of these studies carry pro-
found implications in the clinical setting. Thus, it is
important to determine whether and how ERT can amel-
iorate neural dysfunction.
Estrogen and cognition
Clinical studies demonstrate that estrogen influences
memory and cognition,6,17-22 and can protect against neuro-
degenerative diseases such as AD.10,11,23-30 These findings,
however, are not without controversy. As the results of
more clinical studies become available, we are beginning
to appreciate that the protective actions of estrogen do
not apply in all situations.31-33
Many studies have examined whether ERT improves
cognitive function.The majority of data show that estro-
gen can enhance cognitive function in both young22 and
older women.19,21,34 It appears that by maintaining normal
cognitive function, estrogen may further act to decrease
the risk and delay the onset of AD.10,26-28,35 Importantly,
estrogen does not exert actions on all aspects of mem-
ory. It is critical to consider that memory is a broad term
describing several distinct neural functions, many of
which originate in different and overlapping regions of
the brain. Thus, it is not surprising that estrogen may
influence specific subtypes of memory. For example,
some,17,19,34 but not all,36 studies show that ERT appears
to specifically enhance immediate and delayed recall of
verbal information. Other reports indicate that the ben-
eficial actions of ERT on cognition include improvement
of visuospatial memory.37,38
Estrogen and Alzheimer’s disease
Several studies have examined whether ERT decreases
the risk, delays the onset, or stops the progression of
neurodegeneration caused by AD. Estrogen has been
shown to decrease the risk for AD10 or induce a modest
improvement in cognitive function in individuals with
AD.11,35,39,40 However, other studies have reported no dif-
ference in cognitive function between estrogen- and
placebo-treated individuals.41-43 A recent cohort study43
failed to detect slowing of AD progression or improve-
ment of cognitive and functional outcomes in women
with mild-to-moderate AD treated with Premarin®. The
results of this study and those of other studies31-33 strong-
ly suggest that estrogen may fail to reverse or even halt
a disease process that has already been initiated.
Therefore, while it is clear that estrogen can influence
certain aspects of cognitive function and decrease the
risk for AD, it remains controversial whether it can act
against an existing neurodegenerative condition. Taken
together, the findings of these studies indicate that estro-
gen may protect the brain through primary prevention.
Estrogen and stroke
Our studies on estrogen action against neurodegenera-
tion have focused attention on whether estradiol plays
a role in stroke injury. We, and others, have aggressively
investigated this question since stroke: (i) is a major
form of neurodegeneration that grossly impacts our
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aging population, and (ii) has been successfully repro-
duced in several animal models. To date, most clinical
studies have assessed whether ERT alters the risk and
mortality of stroke,44 but have not addressed whether
estradiol decreases the degree of brain injury resulting
from stroke.
Stroke is a neurodegenerative condition that greatly
impacts the health and livelihood of our aging popula-
tion. It is the third leading cause of death for middle-
aged and older women, and a major health problem that
affects 500 000 Americans each year.45 Interestingly, pre-
menopausal women are at a lower risk for stroke than
men of the same age.46 However, after the menopause
the incidence of cerebrovascular disease rises rapidly.47
These clinical observations parallel statistics on the
prevalence of stroke with regard to age and sex: at a
younger age, women appear to be protected against
stroke, compared with men, but lose this advantage in
their postmenopausal years (Figure 1).48 Together, these
data suggest that endogenous estrogen plays a protec-
tive role against stroke. Since stroke imposes major mor-
bidity and mortality in postmenopausal women, it is crit-
ical to determine whether ERT may decrease the risk
and/or severity of cerebrovascular disease.
Classification of stroke
Stroke results in infarction of the brain. Major causes
and risk factors for stroke include coronary artery dis-
ease, cardiac failure, diabetes, hypertension, atheroscler-
osis, and thrombotic conditions. The overlapping and
often mixed etiologies of stroke can result in two major
types of pathology: ischemic stroke or hemorrhagic
stroke. Briefly, clot(s) in the cerebrovasculature produce
ischemic infarct, and the bursting of cerebral vessel(s)
causes subarachnoid hemorrhage.
Estrogen and stroke risk
Several lines of evidence suggest that ERT may reduce
the likelihood for stroke by modifying risk factors 
that underlie both stroke and coronary heart disease
(CHD).44 For example, estrogen may protect by exerting
beneficial effects on diabetes and on the serum lipid pro-
file.49,50 Interestingly, CHD doubles the risk for stroke and
ERT greatly reduces the risk for CHD (by 30% to 40%).
It thus follows that estrogen may decrease the risk for
stroke in parallel with its protective actions on CHD.
In contrast to protection, estrogen may, under some cir-
cumstances, impose an increased risk for stroke by influ-
encing coagulation and fibrinolysis. Concerns of the
thrombotic potential of estrogen arose from early obser-
vations that oral contraceptives appeared to increase the
risk of venous thrombosis, pulmonary embolism, and
stroke.51 Similarly, ERT in postmenopausal women
appears to be associated with a higher risk of venous
thrombosis during the first year of use.52 However,
whether ERT imposes a risk for ischemic stroke in post-
menopausal women is unclear.We now understand that
the dose of estrogen administered and the route of
estrogen delivery are key components in determining
clotting potential. At higher doses, oral estrogen, which
enters the body via the enterohepatic system, can stim-
ulate the production of thrombogenic factors53,54 pre-
dominantly through its actions on the liver.
Alternatively, lower doses of estrogen, delivered orally
or transdermally, may not significantly affect hemosta-
sis.53,55-57 Importantly, transdermal delivery of estrogen
bypasses enterohepatic circulation and may thus prevent
estrogen-mediated stimulation of thrombogenic factors
in the liver. Collectively, these findings highlight the
importance of low, physiological doses in estrogen
replacement of postmenopausal women.
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Figure 1. Endogenous estrogen may decrease the risk for stroke. Prior to
the menopause, women appear to be protected against the
occurrence of stroke, compared with age-matched men (left).
However, this protection is lost at some time after the
menopause (right), suggesting that endogenous estrogen may
play a protective role against stroke. Data modified from the
American Heart Association (2001).48
ERT and stroke: overview of clinical studies
Studies have only begun to explore the actions of hor-
mone replacement on stroke in the clinical setting. Data
from several human studies clearly indicate that estro-
gen exerts protection against stroke58-61; however, many
studies report either protective trends or no significant
effect of estrogen58,59,62-72 and few report deleterious
effects of estrogen.62,66,73,74 Preliminary results from the
latest clinical study, the Women’s Estrogen for Stroke
Trial (WEST), indicate that estrogen does not protect
against the rate of either nonfatal stroke or death in
postmenopausal women with a history of stroke.75 In
parallel with studies that fail to detect estrogen-medi-
ated protection of the heart in women with cardiovas-
cular disease,16 or of the brain in women with AD,43 the
results of WEST suggest that estrogen does not effec-
tively protect against or reverse a disease process that
has already been initiated.
To date, clinical studies have mainly probed whether
ERT significantly affects the incidence and mortality of
stroke. The outcomes of many of these studies are var-
ied and often appear to be contradictory. Thus, we can-
not yet draw clear conclusions from the existing data
due to several confounding issues. The lack of uniform-
ity among the data in clinical reports may result from
several inconsistencies.44 First, stroke is a mixed group
of diseases with varying etiologies. If ERT decreases or
increases the risk of specific stroke subtypes, effects of
estrogen may be distorted and/or masked when strokes
are grouped together and classified differently among
the studies. Second, it is important to distinguish
between ever and current users of ERT, as these cate-
gories represent two distinct populations of women;
ever users of ERT may demonstrate long-lasting actions
of estrogen, while current users of ERT may exhibit pri-
marily short-term actions of estrogen. Clearly, mixing
the two populations can obscure important effects of
estrogen. Finally, it is critical to identify and probe the
effects of different modes and regimens of ERT since
estrogen action can vary dramatically if it is adminis-
tered (i) in physiological versus pharmacological doses;
(ii) alone or combined with progesterone (cyclic or con-
tinuous); and (iii) orally or transdermally. Since the dis-
tinctions among ERT regimens are not clear in most
clinical studies, it is often difficult to interpret results or,
further, to compare results with the outcomes of other
studies.
Cerebral ischemia: an animal model of stroke
Realistically, even the best, well-designed clinical stud-
ies may not benefit from the experimental advantages
of many basic science studies including clear and uncon-
founded controls, well-controlled environments, and lack
of selection or recall bias.Thus, investigators have devel-
oped animal models of stroke to investigate the patho-
physiology and potential treatments for stroke.
Cerebral artery occlusion
Experimental methods developed to emulate stroke in
animal models produce brain ischemia by blocking
blood flow to the cerebral vasculature. The varieties of
techniques used to induce ischemia differ with regard to
the means of producing ischemia, the site of occlusion,
and the duration of occlusion. We utilized an animal
model of stroke, permanent middle cerebral artery
occlusion (MCAO), to examine the effects of estrogen
in neurodegeneration. Since ischemic infarcts represent
the majority (>70%) of cerebrovascular disease in the
aging population, we adopted an animal model that
reproduces ischemic infarcts. MCAO has been thor-
oughly developed and characterized to study the patho-
physiology and therapeutic possibilities of ischemic
injury. Occlusion, or the blocking of blood flow, of the
middle cerebral artery predominantly affects two major
areas: the cortex and underlying striatum. Permanent
blockage of this artery at its base causes severe meta-
bolic impairment in the striatum because this region
receives no alternative blood perfusion; this character-
izes the “ischemic core.” The cortex, on the other hand,
undergoes moderate metabolic impairment and is
potentially salvageable by effective therapeutic agents
because it receives some perfusion from the anterior
cerebral artery and the vertebral artery76; this character-
izes “ischemic penumbra.”
Ischemia results in cell death
The ischemic brain is exposed to excessive amounts of
glutamate, which leads to massive influxes of calcium
into cells. Although the exact mechanisms of ischemic
injury are not clear, glutamate neurotoxicity is a key
player in the pathogenesis of an ischemic lesion.77-79
Inappropriate rises in intracellular calcium due to glu-
tamate and ion dyshomeostasis can cause moderate or
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irreversible injury, depending on the severity of the
insult.79 An evolving view of trauma in focal cerebral
ischemia is that the severely impaired “ischemic core”
dies by necrotic cell death, a mode of death character-
ized by inflammation and cellular bursting. The moder-
ately injured “ischemic penumbra” dies, in part, by
apoptotic cell death, an orchestrated event of cellular
signaling that results in distinct morphological changes
resembling autodigestion.80 While the exact modes of
ischemic cell death are controversial, several apoptot-
ic factors have been identified as pathogenic or survival
components in ischemic injury.81-87 As discussed below,
many studies, including our own, have investigated
whether estradiol can attenuate cell death resulting
from ischemic injury and whether the mechanisms of
protection against cell death involve suppression of
apoptotic signaling.
Estrogen and neuroprotection: insights from
basic science studies
Estrogen protects against in vivo brain injury
In 1991, a single in vivo report suggested that estradiol
may play a role in protection of the brain.This study, car-
ried out by Hall and colleagues, demonstrated that
female gerbils sustained less neuronal pathology fol-
lowing global ischemia than males.88 Since then, the field
of estrogen and neuroprotection has rapidly expanded
and numerous laboratories have demonstrated that
estrogen exerts profound neuroprotective actions in a
variety of paradigms of brain injury.89 The results of these
studies have clearly shown that that estradiol decreases
the severity of injury in several in vivo models including
cerebral ischemia,90-95 cerebral contusion,96-98 hypoxia,99
and drug-induced toxicity.100
Studies performed using animal models of stroke pro-
vide strong evidence that estradiol is a neuroprotective
factor that profoundly attenuates the degree of ischemic
brain injury. These studies clearly establish that females
uniformly endure less stroke injury than males. Female
gerbils demonstrate less neuronal pathology than males
after ischemia induced by unilateral carotid artery occlu-
sion.88 Likewise, gonadally intact female rats sustain over
50% less infarction than gonadally intact males and
ovariectomized female rats following ischemia induced
by transient occlusion of the middle cerebral artery.94,101
Further, gonadectomized females90-93,102 and males92 that
are treated with estradiol suffer less MCAO-induced
injury than estradiol-depleted controls.
Our work has significantly contributed to the under-
standing of the neuroprotective actions of physiological
levels of estradiol. We have found that low, physiologi-
cal doses of estradiol replacement are sufficient to exert
dramatic protection in the brains of young female rats
(Figure 2).90 Further, we found that middle-aged female
rats remain responsive to the neuroprotective effects of
low estradiol levels.103 Collectively, the results of these
studies suggest that postmenopausal women that are
estrogen-replaced may suffer a decreased degree of
brain injury following a stroke, compared with their
hypoestrogenic counterparts. However, we must be care-
ful in extrapolating from rodents to humans until the
appropriate clinical studies are performed.
Estrogen protects against in vitro neural injury
In addition to in vivo studies, several in vitro studies
have greatly contributed to our understanding of estro-
gen action against degeneration. Many paradigms have
been utilized to investigate whether estrogen can pro-
tect neural cells, in vitro. Studies have been performed
in primary neuronal cultures, mixed astrocyte/neuron
cultures, cell lines, and organotypic cultures. Using these
paradigms, investigators have aimed to reproduce the
deleterious environments found in various neurodegen-
erative conditions such as AD and stroke and have then
tested whether estrogen protects against cell death.
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Figure 2. Physiological levels of estradiol decrease ischemic brain dam-
age following stroke injury. Representative coronal sections
obtained from oil-treated (left) and estradiol-treated (right) rat
brains collected 24 h after the onset of ischemia and stained
with hemotoxylin and eosin. Ischemic injury, produced by per-
manent middle cerebral artery occlusion, appears unstained
and is distributed across the cerebral cortex and striatum.
Pretreatment with low levels of estradiol dramatically decreases
the extent of stroke injury, compared with oil-treated controls. 
Oil Estradiol
In vitro studies clearly establish that estrogen exerts pro-
found protective effects against a variety of neurotoxic
insults. Studies have induced injury through conditions
that mimic AD toxicity,104-107 hypoxia and oxidative
stress,107-113 excitotoxicity,107,111,114-116 and physical injury.117
Thus, studies have examined whether estradiol can sal-
vage cells from death induced by inhibition of mito-
chondrial function, suppression of glucose metabolism,
alteration of nitric oxide production, or administration
of substances such as β-amyloid peptide, excitatory
amino acids, free radicals, and glycoprotein 120.Though
the differing modes of injury are distinct, they may share
similar mechanisms of toxicity and face final common
pathways in the induction of cell death. It remains to be
determined whether estradiol protects against cell death
through parallel or divergent pathways in the different
modes of injury.
Estrogen does not always protect
It is important to appreciate that estrogen does not
always exert beneficial effects. The actions of estrogen
appear to be dictated by the type of estrogen adminis-
tered, dose of estrogen given, and the animal model uti-
lized.The type of estrogen administered impacts the effi-
cacy of its neuroprotective actions. Most studies have
focused attention on the effects of 17β-estradiol since it
is the most biologically active and potent endogenous
estrogen. However, we have gained major insight into
estrogen action through studies that have probed the
effects of 17α-estradiol, an “inactive” stereoisomer that
does not effectively bind and activate ERs. The studies
show that at physiological levels, 17β-estradiol protects
and 17α-estradiol fails to protect against brain injury,110
indicating that ERs are critical to the mechanisms of hor-
mone-mediated protection.12,118 However, the picture
becomes more complex when we consider the dose of
estrogen administered. Although physiological levels of
17α-estradiol fail to protect, pharmacological levels of
both 17β- and 17α-estradiol act to protect12,119 through
mechanisms that are likely to bypass ERs. The results of
these findings highlight the importance of dose and
type/potency of estrogen administered in achieving neuro-
protection. Since a variety of estrogenic compounds are
components of ERT preparations and several “designer”
estrogens are administered or being developed, it will be
critical to assess the efficacies of the wide variety of estro-
gens in promoting beneficial actions in the brain.
Under certain circumstances, 17β-estradiol can either fail
to protect or even harm the brain. While estradiol can
decrease brain injury in the vast majority of studies,
estradiol fails to attenuate cell death in some animal
models.96,120,121 It is possible that when the degree of injury
is too severe, as may be the case in the hippocampus fol-
lowing prolonged global ischemia,120 the actions of estra-
diol are not sufficient to prevent cell death. Under other
circumstances, estradiol can be deleterious to neural
function. In animal models of epilepsy, estradiol lowers
the threshold for seizures and facilitates the induction
and duration of excitatory neural firing.115,122 These data
suggest that ERT may not always exert only beneficial
actions in the brains of postmenopausal women, partic-
ularly in those with a medical history of epilepsy. As we
continue to learn about the complexity of estrogen
action with regards to dose, type of estrogen, and neu-
rological condition, we will be better able to modify and
transform estrogen replacement into therapy that exerts
only beneficial actions in the brains of postmenopausal
women.
Molecular mechanisms of estrogen-mediated
neuroprotection
Estrogen may exert neuroprotective effects through sev-
eral mechanisms: estrogen can act through ER-depen-
dent and ER-independent, genomic as well as nonge-
nomic means to attenuate neural injury. Collectively,
studies demonstrate that the pathway of estrogen action
is influenced by the dose of estrogen administered. In
general, pharmacological levels of estradiol protect the
brain through mechanisms that do not require ERs,
while physiological levels of estradiol protect the brain
through mechanisms that depend upon ERs, as dis-
cussed below.
Estrogen receptor–mediated mechanisms
ERs are critical to our understanding of the mechanisms
of estrogen action. Two ER subtypes, or ERs, exist: the
classic ERα and the recently discovered ERβ.Although,
portions of ERα and ERβ are quite similar in structure,
their distributions throughout the body and the brain are
unique. Their unique regional distributions suggest that
the receptors play very different roles in the body.
Both ERα and ERβ are transcription factors.They bind
estradiol through their ligand-binding domains and,
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upon activation, homodimerize or heterodimerize
through zinc finger structures located in the DNA and
ligand-binding domains.The ER dimer then translocates
to the nucleus and binds to the estrogen-responsive ele-
ments located in the promoters of estrogen-responsive
genes to regulate transcription (Figure 3). ER-regulated
transcription is enhanced by cofactors (coactivators and
corepressors) that bind the ER–DNA complex to either
amplify or diminish transcriptional activation or repres-
sion (Figure 3).
Our long-standing and traditional view of ER action123 is
rapidly transforming as we discover novel and unique
roles for ERs, beyond direct transcriptional modulation.
We now know that ERs interact with signal transduction
pathways,124,125 such as adenylyl cyclase, phosphoinositol-
3-kinase, and/or mitogen-activated kinase (MAPK), or
involve cross-talk with growth factor receptors, such as
trkA and insulin-like growth factor–I (IGF-I) recep-
tor.114,124,126-128 These novel ER-mediated mechanisms may
lead to downstream altered gene expression and/or
altered phosphorylation of proteins to promote estradi-
ol action (Figure 3).
These traditional and novel ER-mediated interactions
may induce a variety of cellular responses that promote
trophic and protective effects in the brain. Physiological
levels of estradiol can enhance synaptic plasticity,129-133
regulate the expression of neurotrophins and cognate
receptors,134-137 and elevate the expression of cell survival
factors.106,138,139 Any or all ER-mediated actions of estra-
diol that enhance the integrity and plasticity of the brain
may ultimately promote neuroprotection.
We investigated the functional roles for ERs in estradiol-
mediated protection against stroke injury and discov-
ered a novel and unique role for ERα in the brain. Our
data revealed that physiological levels of estradiol
require ERs to exert protection against cerebral
ischemia.110,140 Specifically, we utilized transgenic mice
that were knocked out for either ERα or ERβ and
found that the classic ER, ERα, is the critical mechanis-
tic link in the ability of low levels of estradiol to exert
neuroprotection (Figure 4). We have begun to identify
the repertoire of downstream genomic targets of estra-
diol action through ERs and, to date, have reported that
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Figure 3. Estrogen receptors (ERs) act through traditional and novel
mechanisms. This diagram illustrates ERs in their classical roles
as transcription factors and in their newfound roles as com-
ponents of signal transduction pathways. As transcription fac-
tors, ERs bind estradiol, dimerize, and then translocate to the
nucleus. In the nucleus, ERs bind to estrogen-responsive ele-
ments in the promoters of target genes to induce or to sup-
press transcription. Cofactors can modulate the ER–DNA
interactions to either amplify or diminish transcription. In
addition to gene transactivation, ERs may also activate signal
transduction pathways. For example, estradiol stimulates
adenylyl cyclase (AC), one of several ways that it increases
mitogen-activated protein kinase (MAPK) phosphorylation.
Further, estradiol stimulates phosphoinositol-3-kinase (PI3K),
which increases Akt (protein kinase B) phosphorylation. These
effects on signal transduction may turn key proteins on or off,
or ultimately induce genomic actions. 
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Figure 4. Estrogen receptor–α (ERα) is critical in estradiol-mediated pro-
tection of the brain following stroke injury. Estradiol (E)
reduces ischemic infarct in both wildtype mice, WT1 (A) and
WT2 (B), compared with corresponding oil-treated controls
(n=6–10/group) (*P<0.02). Estradiol fails to protect in ERα
knock-out (ERαKO) mice, compared with oil-treated controls
(n=13/group) (A), but continues to protect in (B) ERβKO mice,
compared with oil-treated controls (n=8–9/group) (*P<0.02).
Values represent means±SE. 
Reproduced from reference 140: Dubal DB, Zhu B, Yu B, et al.
Estrogen receptor-α, not -β, is a critical link in estradiol-mediated
protection against brain injury. Proc Natl Acad Sci U S A.
2001;98:1952-1957. Copyright © 2001, National Academy of
Sciences, USA. 
estradiol modulates the expression of a several players
in ischemic brain injury including survival factors,139
immediate early genes,141 neuropeptides,142 and trophic
factors.143
Estrogen receptor–independent mechanisms and actions
Though our studies focus attention on the mechanisms
of ER-dependent, physiological actions of estrogen, it is
very important to understand the mechanisms underly-
ing pharmacological actions of estrogen since these
effects are rapid, immediate, and may be critical to
development of acute treatment of brain injury.
While physiological levels of estradiol generally require
receptor-mediated genomic or nongenomic function for
neuroprotection, pharmacological levels of estradiol
appear to protect through non–ER-mediated effects.
Pharmacological levels of estradiol can rapidly and
reversibly decrease N-methyl-D-aspartate (NMDA)–
induced currents,116 suggesting that it may reduce exci-
tatory cell death caused by neurodegenerative injury.
Furthermore, estrogens can influence members of the
nitric oxide synthase family to induce vasodilatory
actions on cerebral blood vessels144 and thus improve
blood flow to compromised brain regions. Estrogens can
also act as potent antioxidants and inhibit lipid peroxi-
dation88,105,107,112,145-148 through actions that have been shown
to occur via the C3 hydroxyl group located on the phe-
nolic A-ring of the steroids.112,145 These studies88,105,112,145,146
confirm that this antioxidant mechanism requires sup-
raphysiological levels of estrogen, and these findings
may be key in the development of therapeutic approaches
aimed at achieving neuroprotection against injury
induced by oxidative stress.
Conclusion
In summary, a large breadth of clinical and basic science
studies have led to a new appreciation that estradiol acts
far beyond the reproductive axis and exerts profound
protective actions in the adult and aging brain. Though
we have only just begun to identify potential cellular and
molecular mechanisms of this protection, our growing
knowledge of estrogen action in the injured brain will
ultimately lead to a more complete understanding of the
precise mechanisms underlying estradiol-mediated pro-
tection. This knowledge is crucial to developing both
preventative and acute therapies for neurodegenerative
conditions and carries great promise for improving the
quality of lives in our aging population. ❏
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Estrógenos y neuroprotección: 
desde las observaciones clínicas a los 
mecanismos moleculares
Actualmente nosotros sabemos que los estrógenos
son esteroides gonadales pleiotrópicos que ejercen
efectos significativos en la plasticidad y en la sobre-
vida celular del cerebro adulto. Durante el siglo
pasado la duración de la vida de las mujeres ha
aumentado, pero la edad de la menopausia se ha
mantenido constante. Esto significa que ahora las
mujeres pueden vivir más de un tercio de sus vidas
en un estado hipoestrogénico postmenopáusico. El
impacto en el cerebro del hipoestrogenismo pro-
longado constituye ahora una preocupación crítica
de salud ya que nos damos cuenta que estas muje-
res pueden tener un aumento del riesgo de disfun-
ción cognitiva y de neurodegeneración debido a
una variedad de enfermedades. La evidencia que se
ha acumulado tanto de los estudios clínicos como
de ciencias básicas indica que los estrógenos ejer-
cen acciones protectoras críticas ante condiciones
neurodegenerativas como la enfermedad de
Alzheimer y los accidentes vasculares cerebrales. En
este artículo nosotros revisamos los descubrimien-
tos que engloban nuestra comprensión actual de la
acción de los estrógenos contra la neurodegenera-
ción. Estos hallazgos conducen a posibilidades de
gran alcance para mejorar la calidad de vida en
nuestra población que envejece.
Estrogènes et neuroprotection : 
de l’observation clinique aux mécanismes
moléculaires
Nous savons maintenant que les estrogènes sont
des stéroïdes gonadiques pléiotropes qui exercent
d’importants effets sur la plasticité et la survie cel-
lulaire du cerveau de l’adulte. Si l’espérance de vie
des femmes a augmenté au siècle dernier, l’âge de
la ménopause, quant à lui, reste constant. Cela
signifie que les femmes peuvent maintenant passer
plus d’un tiers de leur vie dans un climat postmé-
nopausique, hypoestrogénique. L’impact sur le cer-
veau d’une hypoestrogénicité prolongée est deve-
nu un souci de santé préoccupant car nous réalisons
que ces femmes peuvent être confrontées à un
risque accru de dysfonctionnement cognitif et de
neurodégénérescence secondaires à de nombreuses
maladies. L’accumulation des constatations issues
des études scientifiques cliniques et fondamentales
indique que les estrogènes exercent des actions
protectrices cruciales contre les pathologies neuro-
dégénératives telles que la maladie d’Alzheimer et
l’accident vasculaire cérébral. Nous passons ici en
revue les découvertes qui constituent nos connais-
sances actuelles sur l’action des estrogènes contre
la neurodégénérescence. Ces découvertes ouvrent
la voie à des possibilités d’une portée considérable
pour améliorer la qualité de vie de notre popula-
tion vieillissante.
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